Skip to main content
Erschienen in: Endocrine 3/2019

17.05.2019 | Research Letter

Adrenal insufficiency treated with conventional hydrocortisone leads to elevated levels of Interleukin-6: a pilot study

verfasst von: Amir-Hossein Rahvar, Martin Riesel, Tobias Graf, Birgit Harbeck

Erschienen in: Endocrine | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Excerpt

Adrenal insufficiency is a rare disease with an estimated prevalence of 100–126 cases per million for primary adrenal insufficiency (PAI) and 450 cases per million for secondary/tertiary adrenal insufficiency (SAI/TAI) [1, 2]. Glucocorticoid replacement therapy (GRT) is the gold standard and only viable treatment for AI [3]. The present guideline on PAI recommends the use of hydrocortisone (HC) or prednisolone for GRT [3]. However, currently used GRT regimens inadequately mimic the physiological rhythm of endogenous cortisol secretion leading to temporary hypercortisolism and hypocortisolism [4]. The consequences of these conditions are not completely understood but may be associated with deleterious effects on body composition [5]. In fact, patients with AI on GRT have an increased cardiovascular and cerebrovascular mortality [6, 7]. …
Literatur
1.
Zurück zum Zitat A.C. Willis, F.P. Vince, The prevalence of Addison’s disease in Coventry, UK. Post. Med. J. 73, 286–288 (1997)CrossRef A.C. Willis, F.P. Vince, The prevalence of Addison’s disease in Coventry, UK. Post. Med. J. 73, 286–288 (1997)CrossRef
2.
Zurück zum Zitat H.J. Schneider, G. Aimaretti, I. Kreitschmann-Andermahr, G.K. Stalla, E. Ghigo, Hypopituitarism. Lancet 369, 1461–1470 (2007)CrossRefPubMed H.J. Schneider, G. Aimaretti, I. Kreitschmann-Andermahr, G.K. Stalla, E. Ghigo, Hypopituitarism. Lancet 369, 1461–1470 (2007)CrossRefPubMed
3.
Zurück zum Zitat S.R. Bornstein, B. Allolio, W. Arlt, A. Barthel, A. Don-Wauchope, G.D. Hammer et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 364–389 (2016)CrossRefPubMed S.R. Bornstein, B. Allolio, W. Arlt, A. Barthel, A. Don-Wauchope, G.D. Hammer et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 364–389 (2016)CrossRefPubMed
4.
Zurück zum Zitat A.H. Rahvar, C.S. Haas, S. Danneberg, B. Harbeck, Increased cardiovascular risk in patients with adrenal insufficiency: a short review. Biomed. Res. Int. 2017, 3691913 (2017)CrossRefPubMedPubMedCentral A.H. Rahvar, C.S. Haas, S. Danneberg, B. Harbeck, Increased cardiovascular risk in patients with adrenal insufficiency: a short review. Biomed. Res. Int. 2017, 3691913 (2017)CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat B. Harbeck, P. Kropp, H. Mönig, Effects of short-term nocturnal cortisol replacement on cognitive function and quality of life in patients with primary or secondary adrenal insufficiency: a pilot study. Appl. Psychophysiol. Biofeedback 34, 113–119 (2009)CrossRefPubMed B. Harbeck, P. Kropp, H. Mönig, Effects of short-term nocturnal cortisol replacement on cognitive function and quality of life in patients with primary or secondary adrenal insufficiency: a pilot study. Appl. Psychophysiol. Biofeedback 34, 113–119 (2009)CrossRefPubMed
6.
Zurück zum Zitat H. Filipsson, J.P. Monson, M. Koltowska-Häggström, A. Mattsson, G. Johannsson, The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J. Clin. Endocrinol. Metab. 91, 3954–3961 (2006)CrossRefPubMed H. Filipsson, J.P. Monson, M. Koltowska-Häggström, A. Mattsson, G. Johannsson, The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J. Clin. Endocrinol. Metab. 91, 3954–3961 (2006)CrossRefPubMed
7.
Zurück zum Zitat M. Debono, R.J. Ross, J. Newell-Price, Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur. J. Endocrinol. 160, 719–729 (2009)CrossRefPubMed M. Debono, R.J. Ross, J. Newell-Price, Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur. J. Endocrinol. 160, 719–729 (2009)CrossRefPubMed
8.
Zurück zum Zitat G. Mastorakos, G. Paltoglou, M. Greene, I. Ilias, A. Papamichalopoulos, S. Dimopoulos et al. Inappropriately normal plasma ACTH and cortisol concentrations in the face of increased circulating interleukin-6 concentration in exercise in patients with sarcoidosis. Stress 16, 202–210 (2013)CrossRefPubMed G. Mastorakos, G. Paltoglou, M. Greene, I. Ilias, A. Papamichalopoulos, S. Dimopoulos et al. Inappropriately normal plasma ACTH and cortisol concentrations in the face of increased circulating interleukin-6 concentration in exercise in patients with sarcoidosis. Stress 16, 202–210 (2013)CrossRefPubMed
9.
Zurück zum Zitat D.A. Papanicolaou, C. Tsigos, E.H. Oldfield, G.P. Chrousos, Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency? J. Clin. Endocrinol. Metab. 81, 2303–2306 (1996)CrossRefPubMed D.A. Papanicolaou, C. Tsigos, E.H. Oldfield, G.P. Chrousos, Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency? J. Clin. Endocrinol. Metab. 81, 2303–2306 (1996)CrossRefPubMed
10.
Zurück zum Zitat C. Tsigos, I. Kyrou, G.P. Chrousos, D.A. Papanicolaou, Prolonged suppression of corticosteroid-binding globulin by recombinant human interleukin-6 in man. J. Clin. Endocrinol. Metab. 83, 3379 (1998)CrossRefPubMed C. Tsigos, I. Kyrou, G.P. Chrousos, D.A. Papanicolaou, Prolonged suppression of corticosteroid-binding globulin by recombinant human interleukin-6 in man. J. Clin. Endocrinol. Metab. 83, 3379 (1998)CrossRefPubMed
11.
Zurück zum Zitat N. Sarwar et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379, 1205–1213 (2012)CrossRefPubMed N. Sarwar et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379, 1205–1213 (2012)CrossRefPubMed
12.
Zurück zum Zitat D.I. Swerdlow et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379, 1214–1224 (2012)CrossRefPubMed D.I. Swerdlow et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379, 1214–1224 (2012)CrossRefPubMed
13.
Zurück zum Zitat M. Forss, G. Batcheller, S. Skrtic, G. Johannsson, Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency—a worldwide patient survey. BMC Endocr. Disord. 12, 8 (2012)CrossRefPubMedPubMedCentral M. Forss, G. Batcheller, S. Skrtic, G. Johannsson, Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency—a worldwide patient survey. BMC Endocr. Disord. 12, 8 (2012)CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat G. Johannsson, A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J. Clin. Endocrinol. Metab. 97, 473–481 (2012)CrossRefPubMed G. Johannsson, A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J. Clin. Endocrinol. Metab. 97, 473–481 (2012)CrossRefPubMed
15.
Zurück zum Zitat A.M. Isidori, M.A. Venneri, C. Graziadio, C. Simeoli, D. Fiore, V. Hasenmajer et al. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 6, 173–185 (2018)CrossRefPubMed A.M. Isidori, M.A. Venneri, C. Graziadio, C. Simeoli, D. Fiore, V. Hasenmajer et al. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 6, 173–185 (2018)CrossRefPubMed
16.
Zurück zum Zitat P.M. Ridker, N. Rifai, M.J. Stampfer, C.H. Hennekens, Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101, 1767–1772 (2000)CrossRefPubMed P.M. Ridker, N. Rifai, M.J. Stampfer, C.H. Hennekens, Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101, 1767–1772 (2000)CrossRefPubMed
17.
Zurück zum Zitat B.C. Bacchiega, A.B. Bacchiega, M.J. Usnayo, R. Bedirian, G. Singh, G.D. Pinheiro, Interleukin 6 inhibition and coronary artery disease in a high-risk population: a prospective community-based clinical study. J. Am. Heart Assoc. 6, e005038 (2017)CrossRefPubMedPubMedCentral B.C. Bacchiega, A.B. Bacchiega, M.J. Usnayo, R. Bedirian, G. Singh, G.D. Pinheiro, Interleukin 6 inhibition and coronary artery disease in a high-risk population: a prospective community-based clinical study. J. Am. Heart Assoc. 6, e005038 (2017)CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat L. Brydon, S. Edwards, V. Mohamed-Ali, A. Steptoe, Socioeconomic status and stress-induced increases in interleukin-6. Brain Behav. Immun. 18, 281–290 (2004)CrossRefPubMed L. Brydon, S. Edwards, V. Mohamed-Ali, A. Steptoe, Socioeconomic status and stress-induced increases in interleukin-6. Brain Behav. Immun. 18, 281–290 (2004)CrossRefPubMed
19.
Zurück zum Zitat R. von Känel, B.M. Kudielka, D. Preckel, D. Hanebuth, J.E. Fischer, Delayed response and lack of habituation in plasma interleukin-6 to acute mental stress in men. Brain Behav. Immun. 20, 40–48 (2006)CrossRef R. von Känel, B.M. Kudielka, D. Preckel, D. Hanebuth, J.E. Fischer, Delayed response and lack of habituation in plasma interleukin-6 to acute mental stress in men. Brain Behav. Immun. 20, 40–48 (2006)CrossRef
Metadaten
Titel
Adrenal insufficiency treated with conventional hydrocortisone leads to elevated levels of Interleukin-6: a pilot study
verfasst von
Amir-Hossein Rahvar
Martin Riesel
Tobias Graf
Birgit Harbeck
Publikationsdatum
17.05.2019
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2019
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-019-01956-3

Weitere Artikel der Ausgabe 3/2019

Endocrine 3/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.